GBIM
vs
S&P 500
GBIM
S&P 500
Over the past 12 months, GBIM has underperformed S&P 500, delivering a return of -50% compared to the S&P 500's +16% growth.
Stocks Performance
GBIM vs S&P 500
Performance Gap
GBIM vs S&P 500
Performance By Year
GBIM vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Globeimmune Inc
Glance View
GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is engaged in development of products for the treatment of cancer and infectious diseases. The firm provides Tarmogen platform, which activate the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. The firm's oncology product candidates include GI-6301, GI-6207 and GI-4000. The firm's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.
